Nilotinib Stada (Nilotinib)

Nilotinib is used to target the BCR‑ABL driven pathway in specific hematologic malignancies.

• Chronic myeloid leukemia (CML) in chronic phase: reduces disease progression and improves survival.
• Philadelphia chromosome‑positive CML: achieves molecular and cytogenetic responses in patients resistant or intolerant to prior therapy.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides an additional treatment option in combination regimens for adult patients.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, a fusion protein that drives uncontrolled cell proliferation in Philadelphia chromosome‑positive leukemias. By binding to the ATP‑binding site of BCR‑ABL, it blocks downstream signaling pathways involved in cell growth and survival. The drug also inhibits related kinases such as PDGFR and c‑KIT, contributing to its antitumor activity while sparing normal cells. This targeted inhibition leads to apoptosis of malignant clones and reduces disease burden.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Elevated liver enzymes: mild to moderate increases in ALT or AST.
• Nausea or vomiting: gastrointestinal discomfort occurring early in treatment.
• Diarrhea: watery stools that may be self‑limiting.
• Rash or pruritus: skin irritation or itching.

Serious or Rare Side Effects

• Cardiovascular events: including arterial occlusion, ischemic heart disease, or stroke.
• Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.
• Severe hypersensitivity: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Nilotinib, clinicians should observe several precautionary measures to minimize risk.

• Baseline cardiac assessment: evaluate history of arterial disease before initiating therapy.
• Liver function monitoring: check ALT, AST, and bilirubin regularly during treatment.
• Electrolyte and glucose checks: monitor serum potassium, magnesium, and blood glucose levels.
• Drug interaction review: avoid concomitant use of strong CYP3A4 inhibitors or inducers.
• Pregnancy and lactation: contraindicated; women of childbearing potential must use effective contraception.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protect from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Nilotinib levels and heighten adverse effects.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can reduce drug exposure and compromise efficacy.
• Antacids containing aluminum or magnesium: decrease absorption if taken within 2 hours of the dose.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors (e.g., omeprazole): may modestly reduce bioavailability; timing adjustment recommended.
• Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): monitor for increased statin exposure and muscle toxicity.
• Warfarin: observe INR closely as Nilotinib may affect anticoagulant control.